Literature DB >> 15144953

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.

Ping Zhu1, Elke Martin, Jörg Mengwasser, Peter Schlag, Klaus-Peter Janssen, Martin Göttlicher.   

Abstract

Inappropriate transcriptional repression involving histone deacetylases (HDACs) is a prominent cause for the development of leukemia. We now identify faulty expression of a specific mediator of transcriptional repression in a solid tumor. Loss of the adenomatosis polyposis coli (APC) tumor suppressor induces HDAC2 expression depending on the Wnt pathway and c-Myc. Increased HDAC2 expression is found in the majority of human colon cancer explants, as well as in intestinal mucosa and polyps of APC-deficient mice. HDAC2 is required for, and sufficient on its own to prevent, apoptosis of colonic cancer cells. Interference with HDAC2 by valproic acid largely diminishes adenoma formation in APC(min) mice. These findings point toward HDAC2 as a particularly relevant potential target in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15144953     DOI: 10.1016/s1535-6108(04)00114-x

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  157 in total

Review 1.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 2.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

3.  VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin.

Authors:  Lei Zhang; Guiying Wang; Lin Wang; Chenlin Song; Ye Leng; Xinhua Wang; Jiuhong Kang
Journal:  Mol Cell Biochem       Date:  2011-09-30       Impact factor: 3.396

Review 4.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

Review 5.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

6.  Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.

Authors:  Durgadevi Ravillah; Altaf Mohammed; Li Qian; Misty Brewer; Yuting Zhang; Laura Biddick; Vernon E Steele; Chinthalapally V Rao
Journal:  J Pharmacol Exp Ther       Date:  2013-11-11       Impact factor: 4.030

7.  Role for histone deacetylase 1 in human tumor cell proliferation.

Authors:  Silvia Senese; Katrin Zaragoza; Simone Minardi; Ivan Muradore; Simona Ronzoni; Alfonso Passafaro; Loris Bernard; Giulio F Draetta; Myriam Alcalay; Christian Seiser; Susanna Chiocca
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

8.  Making sense of HDAC2 mutations in colon cancer.

Authors:  John M Mariadason
Journal:  Gastroenterology       Date:  2008-10-11       Impact factor: 22.682

9.  Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.

Authors:  Longgui Wang; Xuanyi Zou; Aaron D Berger; Christian Twiss; Yi Peng; Yirong Li; Jason Chiu; Hongfeng Guo; Jaya Satagopan; Andrew Wilton; William Gerald; Ross Basch; Zhengxin Wang; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

10.  Overexpression of histone deacetylase 2 predicts unfavorable prognosis in human gallbladder carcinoma.

Authors:  Xilin Du; Huadong Zhao; Li Zang; Nuan Song; Tao Yang; Rui Dong; Jikai Yin; Chengguo Wang; Jianguo Lu
Journal:  Pathol Oncol Res       Date:  2012-12-16       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.